Charles River Laboratories Revises Guidance; Sees 2024 Adj. EPS $9.90–$10.20 vs $10.99 Est. (Prior $10.90–$11.40)
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories has revised its guidance for 2024, projecting adjusted EPS to be between $9.90 and $10.20, which is below the previous estimate of $10.99 and prior guidance of $10.90 to $11.40.
August 07, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Charles River Laboratories has revised its 2024 adjusted EPS guidance to $9.90–$10.20, down from the previous estimate of $10.99 and prior guidance of $10.90–$11.40.
The downward revision in EPS guidance indicates potential challenges or lower-than-expected performance for Charles River Laboratories, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100